Clinical Trial

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-23
Trial Details
NCT Number NCT07591090
Lead Sponsor Akeso
Conditions Advanced Breast Cancer
Enrollment 200 participants
Start Date 2026-07-17
Primary Completion 2027-09-01 (estimated)
Study Completion 2029-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-22